共同藥業(300966.SZ):共同生物擬向源科生物購買生產經營所需的土地及地上附着物
格隆匯8月6日丨共同藥業(300966.SZ)公佈,公司全資子公司湖北共同生物科技有限公司(簡稱“共同生物”)擬向湖北源科生物醫藥科技有限公司(簡稱“源科生物”,系公司實際控制人控制下的另一企業)購買生產經營所需的土地及地上附着物,用於新建3000t/d污水處理裝置項目和甲類車間及配套設施生產建設項目,交易各方履行審批程序後,將簽署轉讓協議,轉讓價格合計不超過1,657.03萬元,本次交易資金來源爲共同生物自籌資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.